Cesare Mancuso1,2*- 1Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
- 2Department of Healthcare Surveillance and Bioethics, Section of Pharmacology, Università Cattolica Del Sacro Cuore, Rome, Italy
Heme oxygenase (HO-2) is an enzyme mainly involved in the physiologic turnover of heme and intracellular gas sensing, and it is very abundant in the brain, testes, kidneys and vessels. Since 1990, when HO-2 was discovered, the scientific community has underestimated the role of this protein in health and disease, as attested by the small amount of articles published and citations received. One of the reason that have contributed to the lack of interest in HO-2 was the difficulty in upregulating or inhibiting this enzyme. However, over the last 10 years, novel HO-2 agonists and antagonists have been synthesized, and the availability of these pharmacological tools should increase the appeal of HO-2 as drug target. In particular, these agonists and antagonists could help explain some controversial aspects, such as the neuroprotective versus neurotoxic roles of HO-2 in cerebrovascular diseases. Furthermore, the discovery of HO-2 genetic variants and their involvement in Parkinson’s disease, in particular in males, opens new avenues for pharmacogenetic studies in gender medicine.
1 Introduction
Heme oxygenase (HO) is a well-known family of enzymes primarily involved in heme metabolism (Maines, 1997; Maines, 1988). To date, two HO isoforms have been described, and named HO-1 and HO-2 (Maines, 1997; Maines, 1988). A third HO isoform, HO-3, has been also described, but the strong structural similarities with HO-2 support the idea that HO-3 is a splice variant of HO-2, rather than a distinct isoform (Hayashi et al., 2004). Although HO-1 and HO-2 share the same mechanism of action, namely, the oxidation of heme, the prosthetic group of hemoproteins, in carbon monoxide (CO), ferrous iron and biliverdin (BV), these isoforms differ in regulation and distribution (Maines and Panahian, 2001) (Figure 1; Table 1). Heme oxygenase-1, the inducible isoform, is almost ubiquitous, although quite abundant in hemocatheretic organs (e.g., the liver and spleen) where aged red blood cells are destroyed and hemoglobin is recycled (Maines, 1997). Moreover, under pro-oxidant and/or pro-inflammatory conditions, HO-1 undergoes upregulation and the resulting decrease in redox-active heme and increase in antinflammatory CO both exert a strong antioxidant effect and contribute to the restoration of homeostasis (Mancuso et al., 1997a; Mancuso et al., 1997b; Maines, 1997; Motterlini and Otterbein, 2010; Ryter, 2020). Due to these cytoprotective features, HO-1 is currently considered a main player in the cell stress response and a promising drug target (Mancuso et al., 2006a; Stocker and Perrella, 2006; Motterlini and Foresti, 2014; Salerno et al., 2017; Mancuso, 2022). On the contrary, HO-2, the constitutive isoform, is quite abundant in neurons, testes and kidneys, and is involved in the physiological turnover of heme (Maines, 1997; Maines and Panahian, 2001). This early characterization was challenged, later in the years, by some evidence showing that HO-2 is also involved in the regulation of lipid metabolism and intracellular gas sensing, and can be upregulated in response to few selected stimuli (Table 1) (Raju et al., 1997; Li and Clark, 2001; Shibahara et al., 2007; Vanella et al., 2013). Importantly, HO-1 and HO-2 are not self-sufficient, but they work jointly with the cognate enzyme biliverdin reductase (BVR), which transforms HO-derived BV into bilirubin (BR) (Figure 1), a strong free radical scavenger (Stocker, 2004; Mancuso et al., 2006b; Barone et al., 2009; Mancuso et al., 2012). Along with the reductase activity, BVR is a serine/threonine/tyrosine kinase at the crossroad of many intracellular systems (Gibbs et al., 2012; Mancuso, 2017; Mancuso, 2021).
FIGURE 1. The heme metabolic pathway. In the presence of oxygen and reducing equivalents provided by the NADPH-cytochrome P-450 reductase, both heme oxygenase (HO)-1 and HO-2 oxidatively cleave the hemoproteins’ heme moieties at the α-meso-carbon bridge, resulting in equimolar amounts of ferrous iron (Fe2+), carbon monoxide (CO) and biliverdin. Biliverdin is further reduced at the C10 (γ bridge) by the NAD(P)H-requiring enzyme biliverdin reductase (BVR), yielding bilirubin as the final product.
TABLE 1. Main features of heme oxygenase isoforms.
The distinctive involvement in health and diseases underlies the different appeal of HO isoforms for the scientific community. In particular, the antioxidant and cytoprotective effects of inducible HO-1 in neurodegenerative, cardiovascular and metabolic disorders, as well as in cancer, have fascinated a broad audience of investigators, resulting in more than 14,900 publications. On the other hand, the important, yet limited, physiological role has made HO-2 a niche topic, acknowledged only by a handful experts in the field.
In this context, the aim of the present article is not to provide a detailed and comparative overview of HO-1 and HO-2 features as the interested readers can refer to comprehensive reviews on this topic (Maines and Panahian, 2001; Schipper et al., 2019; Mancuso, 2022). The goal of this article is rather to shed light on HO-2. Starting from an original bibliometric analysis of the literature on HO-2, the attention will be geared towards the most significant scientific achievements which make HO-2 a potential area of successful research and an intriguing target for disease-modifying therapies.
2 Materials and Methods
2.1 Search strategy and literature inclusion
A research was conducted on 10 January 2023 and relevant studies were retrieved from the Pubmed and Scopus archives. The purpose was to include and analyze only papers focusing on HO-2, excluding those in which this latter was only one of many MeSH terms. Therefore, the strategy was to search Pubmed and Scopus for the keywords “heme oxygenase-2” or “haem oxygenase-2” only in the article title. No restrictions were imposed on publication type, year and language. Neither “Erratum” nor “Abstracts” nor “Retracted” articles were included in the analysis.
2.2 Data extraction and statistical analysis
The following information was extracted and analyzed for the included articles: publication type, journal, title, authors, publication year, language, citation count, subject area, Country, Institution and keywords. Microsoft Excel 2013 and Graphpad Prism 8.0.2. Were used for the analysis and graph drawing.
3 Results
In the Pubmed, the query “heme oxygenase-2 OR haem oxygenase-2”, with the keywords typed in the title field, found 161 articles. Since the same query generated 175 results in Scopus, due to the different coverage of literature, the bibliometric analysis included only those papers found in both the databases to standardize the results as described in the Materials and Methods section. The articles retrieved were 159, including 4 conference papers, 2 reviews and 1 editorial. Figure 2 shows the annual number of publications, and highlights that 2003 and 2005 were the years with the highest number of articles published, most of them dealing with the neuroprotective (Chang et al., 2003; Goto et al., 2003; Chen J. et al., 2005; Chen Z. et al., 2005; Namiranian et al., 2005) or cardioprotective effects of HO-2 and its by-product CO (Gagov et al., 2003; Govindaraju et al., 2005; Ishikawa et al., 2005). Table 2 describes the distribution of total publications for subject area. Almost all the articles were written in English, only 2 in Russian and 1 in Chinese.
FIGURE 2. Annual number of articles on heme oxygenase-2. The 159 articles containing the keywords “heme oxygenase-2” or “haem oxygenase-2” in the title, and matching both Pubmed and Scopus archives, were sorted by publication year. 2003 and 2005 were the years with the highest number of articles published. For further information, see text.
TABLE 2. Subject areas of the heme oxygenase-2-related publications published since 1990.
With regard to the citations received by the 159 articles on HO-2, the total count was 7331 and the average number of citations per paper was 46 (max. 618, min. 0). Figure 3 shows that the citations followed a multimodal pattern of distribution over the years, characterized by an early phase (1990–1994) with a rather low count (100 citations), followed by a sharp increase over the next 11 years (2517 citations). A possible explanation for this thriving of citations, peaking in 2006, is that the articles published during the period 1990–1994 explored basic issues related to HO-2 (e.g., structure-activity relationship, regulation or distribution) (Ewing and Maines, 1991; Ewing and Maines, 1992; McCoubrey and Maines, 1994; Weber et al., 1994) and, therefore, were appealing only for few committed scientists. During the following 11 years, instead, HO-2 drew the attention of a broader audience of researchers (including neurologists, cardiologists, pulmonologists and gastroenterologists), who had been fascinated by a significant number of papers reporting the biological effects of HO-2 in organs and tissues (Zakhary et al., 1996; Canning and Fischer, 1998; Miller et al., 1998; Doré et al., 1999a; Doré et al., 1999b; Cao et al., 2000). The inevitable decline, which began in 2007 and still persists, reflects a lack of interest in HO-2 due to the overwhelming attention captured by HO-1, whose involvement in several cytoprotective functions, including the adaptive stress response, mesmerized the scientific community (Calabrese et al., 2010; Catino et al., 2016; Mhillaj et al., 2018). For instance, free radical overproduction is the common denominator of many diseases, such as nephropathies, and HO-1 upregulation in tubules and glomeruli counteracts oxidative damage and helps in preventing the progression of renal dysfunction into end-stage renal disease (Wiesel et al., 2001; Chung and Perrella, 2004; Lever et al., 2016). The evidence that HO-1 knockout mouse exhibits exacerbation of chronic renovascular hypertension and acute renal failure, further confirms the importance of this isoform in renal pathophysiology (Wiesel et al., 2001). These findings mutually support the hypothesis that HO-2, despite being quite abundant in the kidney, is unable to compensate for the loss of HO-1 and contrast the progressive worsening of renal function. A reasonable explanation for this failure is the inability of HO-2 to undergo upregulation in response to oxidative stress and prevent kidney injury.
FIGURE 3. Annual number of citations received by the publications on heme oxygenase-2 (HO-2). The total citation count received by the 159 papers focusing on HO-2 was 7331. A multimodal pattern of distribution over the years can be identified: an early phase (1990–1994) characterized by a low count (100 citations), followed by a sharp increase over the next 11 years (2517 citations), a peak in 2006 and a progressive decrease, starting in 2007 and still persisting. For further information, see text.
The analysis of the number of published papers along with the citations received, allows tracing the research groups who mainly contributed to the advancement of this field. Mahin Maines and her Fellows, at the University of Rochester, paved the way in 1990, providing dozens of milestone articles covering basic and applied aspects of HO-2. Shigeki Shibahara and Collaborators, at the Yamagata University and then at the Tohoku University, focused on the hypoxia-related regulation of HO-2 since 1995 and were the first to propose the novel role of this protein as an oxygen sensor in 2006. Since 1996, at the Johns Hopkins University, Solomon H. Snyder and his research group have provided novel insights about the neuroprotective effects of HO-2 and its by-product CO. Together with his former Fellow, Sylvain Dorè, Solomon H. Snyder also highlighted the neuroprotective effects of HO-2-derived BR. At the Thomas Jefferson University, Raymond F. Regan and his group have focused the attention on the neuroprotective versus neurotoxic effects of HO-2 since 2003. In 2007 Stephen W. Ragsdale’s research group, at the University of Nebraska, ideally passed the relay, by working on the heme-HO-2 interaction and the transcription factor-based activation of this enzyme. The Ragsdale group published the last paper on HO-2 a few months ago. Interestingly, among the 10 most-cited articles (Table 3), 4 papers were authored by Mahin D. Maines’ and 3 by Solomon H. Snyder’s laboratories.
TABLE 3. The top 10 most-cited articles on heme oxygenase-2.
4 Discussion
Over the years, HO-2 has received far less attention from the scientific community than HO-1. The reasons for this underestimation can be traced back to the HO-2 constitutive activity and poor inducibility (Table 1). These features reduced researchers’ appreciation for HO-2, in particular clinicians, who felt the impossibility to explore the applied outcomes of HO-2 upregulation, as an insurmountable hurdle. In light of this, it is not surprising that most of the article published since 1990 falls in the basic subject area of Biochemistry, Genetics and Molecular Biology (Table 2). This trend is confirmed when considering the 10 most-cited articles, 6 of which address the activity, regulation and localization of HO-2 (Table 3). Among the articles listed in Table 3 is the one by Susumu Tonegawa’s group describing the HO-2 null mouse, an experimental model used worldwide to investigate the many roles of the constitutive isoform and its by-products (Poss et al., 1995; Zakhary et al., 1997; Doré et al., 1999a). This transgenic mouse exhibits a significant downregulation of HO-2 gene expression in target organs, such as the brain and testes, but it is fertile and maintains physiological grooming and feeding behaviors (Poss et al., 1995). Moreover, neither the brain nor the peripheral organs of the HO-2 null mouse display significant histological modifications with respect to the wild-type animal (Poss et al., 1995). Later studies have expanded the knowledge about the HO-2 null phenotype and unravelled the involvement of this isoform in both the non-adrenergic-non cholinergic relaxation of the gut and antinflammatory response and wound healing and endothelial cell function (Zakhary et al., 1997; Bellner et al., 2015; 2009; Halilovic et al., 2011). As far as I know, HO-2 deficiency has not been described in humans, yet.
The role of HO-2 as a drug target has also been neglected: just to clarify, only 11 publications fall in the subject area of Pharmacology, Toxicology and Pharmaceutics (Table 2). In this regard, only a couple of articles have explored the link between HO-2 and drugs, namely, those by Chen Z. et al. (2005) and Li and Clark (2001), which described the involvement of rat HO-2 in either the neuroprotective effects of quetiapine and venlafaxine or the morphine-induced tolerance/withdrawal phenomena. However, a careful analysis of the literature published after 2005 allows gathering significant pieces of evidence supporting the role of HO-2 as drug target. In 2011–2013, Kanji Nakatsu and co-workers reported that menadione and clemizole, two well-known drugs, displayed agonist and antagonist activities on HO-2, respectively (Vukomanovic et al., 2011; Vlahakis et al., 2013). These findings were confirmed and extended by other scientists who synthesized and tested novel menadione- and clemizole-derived agonists and antagonists, with improved potency/selectivity on HO-2 (Kong et al., 2015; Salerno et al., 2015; Intagliata et al., 2019; Floresta et al., 2020). Unfortunately, the availability of both HO-2 activators and inhibitors did not encourage scientists to perform ad hoc studies to address the effects of these pharmacological tools in animal models of diseases, and these interesting lines of research, worthy of further study, remained almost unknown (the citations received by the related papers are in the range 4–52). On the contrary, it is my opinion that these activators/inhibitors would be very useful to clarify some controversial aspects of HO-2, such as those highlighted below.
The role of HO-2 in cerebrovascular diseases is still unclear, because some evidence suggests that the enzyme is neuroprotective, whereas other studies support the opposite hypothesis (Doré et al., 1999a; Doré et al., 2000; Goto et al., 2003; Qu et al., 2007; Chen-Roetling et al., 2014; Goto et al., 2018). A possible explanation for this apparent conundrum is the experimental protocol used. The studies suggesting the neurotoxic effects of HO-2 were carried out in HO-2 null mice whose brains were removed 15–17 days postpartum, cortical neurons isolated and cultured for 12–16 days in vitro and then exposed to exogenous blood or hemin to mimic the hemorrhagic injury. Conversely, the articles dealing with the neuroprotective effects of HO-2 were performed in adult HO-2 null mice, exposed to middle-cerebral artery occlusion (1 h occlusion followed by 23 h reperfusion) or collagenase injection, to mimic ischemia or hemorrhage, respectively, and whose brains were removed and analyzed just after the end of the experiments without any further in vitro manipulation. Although it is necessary to use a cautious approach, it is still essential to consider that these divergent results may also depend on the animal model itself. Indeed, the products of many genes are essential for normal function, and inactivating these genes may induce age-dependent, morphological or physiological abnormalities (Nelson, 1997). The lack of HO-2, the main isozyme in the central nervous system involved in the synthesis of neuroprotective CO and BR, could have impaired the brain response to injury. The young age of the HO-2 knockout mice whose brains were processed to prepare neuronal cultures, and the long incubation of dispersed neurons before in vitro treatments, could have contributed to exacerbate the toxicity of exogenous blood or hemin. The possible age-dependent compensative overexpression of antioxidant genes, including HO-1, occurring in adult HO-2 null mice exposed to either in vitro or in vivo ischemia/hemorrhage, is a confounding factor not completely resolved, yet. The availability of HO-2 inhibitors could help to design comparable studies in adult mice with normally developed brains, without any compensative gene overexpression, providing researchers the possibility to confirm previous results or propose novel hypotheses. The possibility to modulate HO-2 in another rodent species frequently used to induce cerebral ischemia or hemorrhage, such as the rat, is another advantage provided by the pharmacological tools and should be taken into proper consideration.
Interestingly, HO-2 could be a new target for pharmacogenetic studies. The HO-2 genetic variants rs2270363 and rs1051308 (−42 + 1444A>G-HMOX2 and c.544G>A polymorphisms, respectively) have been linked to Parkinson’s disease (PD). The homozygous G/G genotype of both the rs2270363 and rs1051308 variants was associated with the risk of developing PD in Spanish and Han Chinese subjects, respectively (Ayuso et al., 2011; Tian et al., 2017). Noteworthy, the GG genotype of rs1051308 variant increases the risk of PD in Han Chinese men, but not in women (Tian et al., 2017). The relevance of these important studies (gone almost unnoticed, as attested by the citation count of 3 and 16 for the most recent and the oldest article, respectively) could be even greater considering that they fall into two hot areas of interest, such as geriatrics and gender medicine.
In conclusion, the purpose of this article will be achieved if the readers, in particular young scientists not yet committed to a specific area of research, get passionate about HO-2 and its unexplored potential as drug target. The availability of selective HO-2 agonists and antagonists is indeed a plus to take advantage of. At the meantime, this paper will have hit the mark if researchers give the right credit to bibliometric indexes, considering the number of citations of an article as a misleading index, at times. The history of HO-2 should be taken as an example. Indeed, as discussed in this article, ideas for new discoveries can also be found in apparently niche topics, as long as the scientist is fully aware of the research field and its translational potential.
Data availability statement
Publicly available datasets were analyzed in this study. This data can be found here: www.pubmed.ncbi.nlm.nih.gov www.scopus.com.
Author contributions
CM designed the study, analyzed the data, interpreted the results and wrote the paper.
Conflict of interest
The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Ayuso, P., Martínez, C., Lorenzo-Betancor, O., Pastor, P., Luengo, A., Jiménez-Jiménez, F. J., et al. (2011). A polymorphism located at an ATG transcription start site of the heme oxygenase-2 gene is associated with classical Parkinson's disease. Pharmacogenet. Genomics. 21, 565–571. doi:10.1097/FPC.0b013e328348f729
Barone, E., Trombino, S., Cassano, R., Sgambato, A., De Paola, B., Di Stasio, E., et al. (2009). Characterization of the S-denitrosylating activity of bilirubin. J. Cell. Mol. Med. 13, 2365–2375. doi:10.1111/j.1582-4934.2009.00680.x
Bellner, L., Marrazzo, G., van Rooijen, N., Dunn, M. W., Abraham, N. G., and Schwartzman, M. L. (2015). Heme oxygenase-2 deletion impairs macrophage function: Implication in wound healing. Faseb. J. 29, 105–115. doi:10.1096/fj.14-256503
Bellner, L., Martinelli, L., Halilovic, A., Patil, K., Puri, N., Dunn, M. W., et al. (2009). Heme oxygenase-2 deletion causes endothelial cell activation marked by oxidative stress, inflammation, and angiogenesis. J. Pharmacol. Exp. Ther. 331, 925–932. doi:10.1124/jpet.109.158352
Calabrese, V., Cornelius, C., Trovato, A., Cavallaro, M., Mancuso, C., Di Rienzo, L., et al. (2010). The hormetic role of dietary antioxidants in free radical-related diseases. Curr. Pharm. Des. 16, 877–883. doi:10.2174/138161210790883615
Canning, B. J., and Fischer, A. (1998). Localization of heme oxygenase-2 immunoreactivity to parasympathetic ganglia of human and Guinea-pig airways. Am. J. Respir. Cell. Mol. Biol. 18, 279–285. doi:10.1165/ajrcmb.18.2.3029
Cao, L., Blute, T. A., and Eldred, W. D. (2000). Localization of heme oxygenase-2 and modulation of cGMP levels by carbon monoxide and/or nitric oxide in the retina. Vis. Neurosci. 17, 319–329. doi:10.1017/s0952523800173018
Catino, S., Paciello, F., Miceli, F., Rolesi, R., Troiani, D., Calabrese, V., et al. (2016). Ferulic acid regulates the nrf2/heme oxygenase-1 system and counteracts trimethyltin-induced neuronal damage in the human neuroblastoma cell line SH-SY5Y. Front. Pharmacol. 6, 305. doi:10.3389/fphar.2015.00305
Chang, E. F., Wong, R. J., Vreman, H. J., Igarashi, T., Galo, E., Sharp, F. R., et al. (2003). Heme oxygenase-2 protects against lipid peroxidation-mediated cell loss and impaired motor recovery after traumatic brain injury. J. Neurosci. 23, 3689–3696. doi:10.1523/JNEUROSCI.23-09-03689.2003
Chen, J., Tu, Y., Connolly, E. C., and Ronnett, G. V. (2005a). Heme oxygenase-2 protects against glutathione depletion-induced neuronal apoptosis mediated by bilirubin and cyclic GMP. Curr. Neurovasc. Res. 2, 121–131. doi:10.2174/1567202053586767
Chen, Z., Xu, H., Haimano, S., Li, X., and Li, X. M. (2005b). Quetiapine and venlafaxine synergically regulate heme oxygenase-2 protein expression in the hippocampus of stressed rats. Neurosci. Lett. 389, 173–177. doi:10.1016/j.neulet.2005.07.040
Chen-Roetling, J., Cai, Y., and Regan, R. F. (2014). Neuroprotective effect of heme oxygenase-2 knockout in the blood injection model of intracerebral hemorrhage. Bmc. Res. Notes. 7, 561. doi:10.1186/1756-0500-7-561
Chung, S. W., and Perrella, M. A. (2004). Role of HO-1 in renoprotection: Location, location, location. Kidney Int. 65, 1968–1969. doi:10.1111/j.1523-1755.2004.00611.x
Doré, S., Goto, S., Sampei, K., Blackshaw, S., Hester, L. D., Ingi, T., et al. (2000). Heme oxygenase-2 acts to prevent neuronal death in brain cultures and following transient cerebral ischemia. Neuroscience 99, 587–592. doi:10.1016/s0306-4522(00)00216-5
Doré, S., Sampei, K., Goto, S., Alkayed, N. J., Guastella, D., Blackshaw, S., et al. (1999a). Heme oxygenase-2 is neuroprotective in cerebral ischemia. Mol. Med. 5, 656–663. doi:10.1007/bf03401984
Doré, S., Takahashi, M., Ferris, C. D., Zakhary, R., Hester, L. D., Guastella, D., et al. (1999b). Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury. Proc. Natl. Acad. Sci. U. S. A. 96, 2445–2450. doi:10.1073/pnas.96.5.2445
Ewing, J. F., and Maines, M. D. (1992). In situ hybridization and immunohistochemical localization of heme oxygenase-2 mRNA and protein in normal rat brain: Differential distribution of isozyme 1 and 2. Mol. Cell. Neurosci. 3, 559–570. doi:10.1016/1044-7431(92)90068-d
Ewing, J. F., and Maines, M. D. (1991). Rapid induction of heme oxygenase 1 mRNA and protein by hyperthermia in rat brain: Heme oxygenase 2 is not a heat shock protein. Proc. Natl. Acad. Sci. U. S. A. 88, 5364–5368. doi:10.1073/pnas.88.12.5364
Floresta, G., Fallica, A. N., Romeo, G., Sorrenti, V., Salerno, L., Rescifina, A., et al. (2020). Identification of a potent heme oxygenase-2 (HO-2) inhibitor by targeting the secondary hydrophobic pocket of the HO-2 Western region. Bioorg. Chem. 104, 104310. doi:10.1016/j.bioorg.2020.104310
Gagov, H., Kadinov, B., Hristov, K., Boev, K., Itzev, D., Bolton, T., et al. (2003). Role of constitutively expressed heme oxygenase-2 in the regulation of Guinea pig coronary artery tone. Pflugers. Arch. 446, 412–421. doi:10.1007/s00424-002-1003-x
Gibbs, P. E., Tudor, C., and Maines, M. D. (2012). Biliverdin reductase: More than a namesake - the reductase, its peptide fragments, and biliverdin regulate activity of the three classes of protein kinase C. Front. Pharmacol. 3, 31. doi:10.3389/fphar.2012.00031
Goto, S., Morikawa, T., Kubo, A., Takubo, K., Fukuda, K., Kajimura, M., et al. (2018). Quantitative imaging mass spectroscopy reveals roles of heme oxygenase-2 for protecting against transhemispheric diaschisis in the brain ischemia. J. Clin. Biochem. Nutr. 63, 70–79. doi:10.3164/jcbn.17-136
Goto, S., Sampei, K., Alkayed, N. J., Doré, S., and Koehler, R. C. (2003). Characterization of a new double-filament model of focal cerebral ischemia in heme oxygenase-2-deficient mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R222–R230. doi:10.1152/ajpregu.00067.2003
Govindaraju, V., Teoh, H., Hamid, Q., Cernacek, P., and Ward, M. E. (2005). Interaction between endothelial heme oxygenase-2 and endothelin-1 in altered aortic reactivity after hypoxia in rats. Am. J. Physiol. Heart Circ. Physiol. 288, H962–H970. doi:10.1152/ajpheart.01218.2003
Halilovic, A., Patil, K. A., Bellner, L., Marrazzo, G., Castellano, K., Cullaro, G., et al. (2011). Knockdown of heme oxygenase-2 impairs corneal epithelial cell wound healing. J. Cell. Physiol. 226, 1732–1740. doi:10.1002/jcp.22502
Hayashi, S., Omata, Y., Sakamoto, H., Higashimoto, Y., Hara, T., Sagara, Y., et al. (2004). Characterization of rat heme oxygenase-3 gene. Implication of processed pseudogenes derived from heme oxygenase-2 gene. Gene 336, 241–250. doi:10.1016/j.gene.2004.04.002
Intagliata, S., Salerno, L., Ciaffaglione, V., Leonardi, C., Fallica, A. N., Carota, G., et al. (2019). Heme oxygenase-2 (HO-2) as a therapeutic target: Activators and inhibitors. Eur. J. Med. Chem. 183, 111703. doi:10.1016/j.ejmech.2019.111703
Ishikawa, M., Kajimura, M., Adachi, T., Maruyama, K., Makino, N., Goda, N., et al. (2005). Carbon monoxide from heme oxygenase-2 Is a tonic regulator against NO-dependent vasodilatation in the adult rat cerebral microcirculation. Circ. Res. 97, e104–e114. doi:10.1161/01.RES.0000196681.34485.ec
Kong, X., Vukomanovic, D., Nakatsu, K., and Szarek, W. A. (2015). Structure-activity relationships of 1,2-disubstituted benzimidazoles: Selective inhibition of heme oxygenase-2 activity. ChemMedChem 10, 1435–1441. doi:10.1002/cmdc.201500128
Lever, J. M., Boddu, R., George, J. F., and Agarwal, A. (2016). Heme oxygenase-1 in kidney health and disease. Antioxid. Redox. Signal. 25, 165–183. doi:10.1089/ars.2016.6659
Li, X., and Clark, J. D. (2001). Spinal cord nitric oxide synthase and heme oxygenase limit morphine induced analgesia. Brain. Res. Mol. Brain. Res. 95, 96–102. doi:10.1016/s0169-328x(01)00251-0
Maines, M. D. (1988). Heme oxygenase: Function, multiplicity, regulatory mechanisms, and clinical applications. Faseb. J. 2, 2557–2568. doi:10.1096/fasebj.2.10.3290025
Maines, M. D., and Panahian, N. (2001). The heme oxygenase system and cellular defense mechanisms. Do HO-1 and HO-2 have different functions? Adv. Exp. Med. Biol. 502, 249–272. doi:10.1007/978-1-4757-3401-0_17
Maines, M. D. (1997). The heme oxygenase system: A regulator of second messenger gases. Annu. Rev. Pharmacol. Toxicol. 37, 517–554. doi:10.1146/annurev.pharmtox.37.1.517
Mancuso, C., Barone, E., Guido, P., Miceli, F., Di Domenico, F., Perluigi, M., et al. (2012). Inhibition of lipid peroxidation and protein oxidation by endogenous and exogenous antioxidants in rat brain microsomes in vitro. Neurosci. Lett. 518, 101–105. doi:10.1016/j.neulet.2012.04.062
Mancuso, C. (2017). Bilirubin and brain: A pharmacological approach. Neuropharmacology 118, 113–123. doi:10.1016/j.neuropharm.2017.03.013
Mancuso, C. (2021). Biliverdin reductase as a target in drug research and development: Facts and hypotheses. Free. Radic. Biol. Med. 172, 521–529. doi:10.1016/j.freeradbiomed.2021.06.034
Mancuso, C., Bonsignore, A., Capone, C., Di Stasio, E., and Pani, G. (2006b). Albumin-bound bilirubin interacts with nitric oxide by a redox mechanism. Antioxid. Redox. Signal. 8, 487–494. doi:10.1089/ars.2006.8.487
Mancuso, C., Perluigi, M., Cini, C., De Marco, C., Giuffrida Stella, A. M., and Calabrese, V. (2006a). Heme oxygenase and cyclooxygenase in the central nervous system: A functional interplay. J. Neurosci. Res. 84, 1385–1391. doi:10.1002/jnr.21049
Mancuso, C., Pistritto, G., Tringali, G., Grossman, A. B., Preziosi, P., and Navarra, P. (1997a). Evidence that carbon monoxide stimulates prostaglandin endoperoxide synthase activity in rat hypothalamic explants and in primary cultures of rat hypothalamic astrocytes. Brain. Res. Mol. Brain. Res. 45, 294–300. doi:10.1016/s0169-328x(96)00258-6
Mancuso, C., Preziosi, P., Grossman, A. B., and Navarra, P. (1997b). The role of carbon monoxide in the regulation of neuroendocrine function. Neuroimmunomodulation 4, 225–229. doi:10.1159/000097340
Mancuso, C. (2022). The brain heme oxygenase/biliverdin reductase system as a target in drug research and development. Expert. Opin. Ther. Targets. 26, 361–374. doi:10.1080/14728222.2022.2052848
McCoubrey, W. K., and Maines, M. D. (1994). The structure, organization and differential expression of the gene encoding rat heme oxygenase-2. Gene 139, 155–161. doi:10.1016/0378-1119(94)90749-8
Mhillaj, E., Catino, S., Miceli, F. M., Santangelo, R., Trabace, L., Cuomo, V., et al. (2018). Ferulic acid improves cognitive skills through the activation of the heme oxygenase system in the rat. Mol. Neurobiol. 55, 905–916. doi:10.1007/s12035-017-0381-1
Miller, S. M., Farrugia, G., Schmalz, P. F., Ermilov, L. G., Maines, M. D., and Szurszewski, J. H. (1998). Heme oxygenase 2 is present in interstitial cell networks of the mouse small intestine. Gastroenterology 114, 239–244. doi:10.1016/s0016-5085(98)70473-1
Motterlini, R., and Foresti, R. (2014). Heme oxygenase-1 as a target for drug discovery. Antioxid. Redox. Signal. 20, 1810–1826. doi:10.1089/ars.2013.5658
Motterlini, R., and Otterbein, L. E. (2010). The therapeutic potential of carbon monoxide. Nat. Rev. Drug. Discov. 9, 728–743. doi:10.1038/nrd3228
Namiranian, K., Koehler, R. C., Sapirstein, A., and Doré, S. (2005). Stroke outcomes in mice lacking the genes for neuronal heme oxygenase-2 and nitric oxide synthase. Curr. Neurovasc. Res. 2, 23–27. doi:10.2174/1567202052773517
Nelson, R. J. (1997). The use of genetic "knockout" mice in behavioral endocrinology research. Horm. Behav. 31, 188–196. doi:10.1006/hbeh.1997.1381
Poss, K. D., Thomas, M. J., Ebralidze, A. K., O'Dell, T. J., and Tonegawa, S. (1995). Hippocampal long-term potentiation is normal in heme oxygenase-2 mutant mice. Neuron 15, 867–873. doi:10.1016/0896-6273(95)90177-9
Qu, Y., Chen-Roetling, J., Benvenisti-Zarom, L., and Regan, R. F. (2007). Attenuation of oxidative injury after induction of experimental intracerebral hemorrhage in heme oxygenase-2 knockout mice. J. Neurosurg. 106, 428–435. doi:10.3171/jns.2007.106.3.428
Raju, V. S., McCoubrey, W. K., and Maines, M. D. (1997). Regulation of heme oxygenase-2 by glucocorticoids in neonatal rat brain: Characterization of a functional glucocorticoid response element. Biochim. Biophys. Acta. 1351, 89–104. doi:10.1016/s0167-4781(96)00183-2
Ryter, S. W. (2020). Therapeutic potential of heme oxygenase-1 and carbon monoxide in acute organ injury, critical illness, and inflammatory disorders. Antioxidants (Basel). 9, 1153. doi:10.3390/antiox9111153
Salerno, L., Pittalà, V., Romeo, G., Modica, M. N., Marrazzo, A., Siracusa, M. A., et al. (2015). Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines. Eur. J. Med. Chem. 96, 162–172. doi:10.1016/j.ejmech.2015.04.003
Salerno, L., Romeo, G., Modica, M. N., Amata, E., Sorrenti, V., Barbagallo, I., et al. (2017). Heme oxygenase-1: A new druggable target in the management of chronic and acute myeloid leukemia. Eur. J. Med. Chem. 142, 163–178. doi:10.1016/j.ejmech.2017.07.031
Schipper, H. M., Song, W., Tavitian, A., and Cressatti, M. (2019). The sinister face of heme oxygenase-1 in brain aging and disease. Prog. Neurobiol. 172, 40–70. doi:10.1016/j.pneurobio.2018.06.008
Shibahara, S., Han, F., Li, B., and Takeda, K. (2007). Hypoxia and heme oxygenases: Oxygen sensing and regulation of expression. Antioxid. Redox. Signal. 9, 2209–2225. doi:10.1089/ars.2007.1784
Stocker, R. (2004). Antioxidant activities of bile pigments. Antioxid. Redox. Signal. 6, 841–849. doi:10.1089/ars.2004.6.841
Stocker, R., and Perrella, M. A. (2006). Heme oxygenase-1: A novel drug target for atherosclerotic diseases? Circulation 114, 2178–2189. doi:10.1161/CIRCULATIONAHA.105.598698
Tian, S., Yang, X., Zhao, Q., Zheng, J., Huang, H., Chen, Y., et al. (2017). Association between a heme oxygenase-2 genetic variant and risk of Parkinson's disease in Han Chinese. Neurosci. Lett. 642, 119–122. doi:10.1016/j.neulet.2017.02.008
Vanella, L., Li Volti, G., Guccione, S., Rappazzo, G., Salvo, E., Pappalardo, M., et al. (2013). Heme oxygenase-2/adiponectin protein-protein interaction in metabolic syndrome. Biochem. Biophys. Res. Commun. 432, 606–611. doi:10.1016/j.bbrc.2013.02.037
Vlahakis, J. Z., Vukomanovic, D., Nakatsu, K., and Szarek, W. A. (2013). Selective inhibition of heme oxygenase-2 activity by analogs of 1-(4-chlorobenzyl)-2-(pyrrolidin-1-ylmethyl)-1H-benzimidazole (clemizole): Exploration of the effects of substituents at the N-1 position. Bioorg. Med. Chem. 21, 6788–6795. doi:10.1016/j.bmc.2013.07.050
Vukomanovic, D., McLaughlin, B. E., Rahman, M. N., Szarek, W. A., Brien, J. F., Jia, Z., et al. (2011). Selective activation of heme oxygenase-2 by menadione. Can. J. Physiol. Pharmacol. 89, 861–864. doi:10.1139/y11-091
Weber, C. M., Eke, B. C., and Maines, M. D. (1994). Corticosterone regulates heme oxygenase-2 and NO synthase transcription and protein expression in rat brain. J. Neurochem. 63, 953–962. doi:10.1046/j.1471-4159.1994.63030953.x
Wiesel, P., Patel, A. P., Carvajal, I. M., Wang, Z. Y., Pellacani, A., Maemura, K., et al. (2001). Exacerbation of chronic renovascular hypertension and acute renal failure in heme oxygenase-1-deficient mice. Circ. Res. 88, 1088–1094. doi:10.1161/hh1001.091521
Zakhary, R., Gaine, S. P., Dinerman, J. L., Ruat, M., Flavahan, N. A., and Snyder, S. H. (1996). Heme oxygenase 2: Endothelial and neuronal localization and role in endothelium-dependent relaxation. Proc. Natl. Acad. Sci. U. S. A. 93, 795–798. doi:10.1073/pnas.93.2.795
Keywords: bilirubin, carbon monoxide, drug research and development, gender medicine, neuroprotection, Parkinson’s disease, translational pharmacology
Citation: Mancuso C (2023) The impact of heme oxygenase-2 on pharmacological research: A bibliometric analysis and beyond. Front. Pharmacol. 14:1156333. doi: 10.3389/fphar.2023.1156333
Received: 01 February 2023; Accepted: 06 April 2023;
Published: 19 April 2023.
Edited by:
Gian Marco Leggio, University of Catania, ItalyReviewed by:
Leo E. Otterbein, Harvard Medical School, United StatesDavid E. Stec, University of Mississippi Medical Center, United States
Copyright © 2023 Mancuso. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cesare Mancuso, Y2VzYXJlLm1hbmN1c29AdW5pY2F0dC5pdA==